HIV infection and antiretroviral therapy: Effect on hepatitis C virus quasispecies variability

Journal of Infectious Diseases

Volumn 193, Issue 9, 2006, Pages 1211-1218

  Shuhart, Margaret C ^a,b   Sullivan, Daniel G ^a   Bekele, Kirubeal ^a   Harrington, Robert D ^a   Kitahata, Mari M ^a   Mathisen, Terri L ^a   Thomassen, Lisa V ^a   Emerson, Scott S ^a   Gretch, David R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENETIC HETEROGENEITY; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; VARIATION (GENETICS);

EID: 33646054891     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/502974     Document Type: Article

References (47)

1. Shuhart MC, Sullivan DG, Bekele K, et al. Highly active antiretroviral therapy is associated with hepatitis C quasispecies variability in patients with hepatitis C and HIV coinfection [abstract]. Hepatology 2003; 38:346A.
2. Soriano V, Rodriguez-Rosado R, Garcia-Samaniego J. Management of chronic hepatitis C in HIV-infected patients. AIDS 1999; 13:539-46.
3. Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta VA. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999; 29:150-4.
4. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-7.
5. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-9.
6. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993; 6:602-10.
7. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994; 87:555-61.
8. Rockstroh JK, Spengler U, Sudhop T, et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV Am J Gastroenterol 1996; 91:2563-8.
9. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-8.
10. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-7.
11. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-13.
12. Weiner AJ, Geysen HM, Christopherson C, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci USA 1992; 89:3468-72.
13. Wilson JJ, Polyak SJ, Day TD, Gretch DR. Characterization of simple and complex hepatitis C virus quasispecies by heteroduplex gel shift analysis: correlation with nucleotide sequencing. J Gen Virol 1995; 76:1763-71.
14. van Doorn LJ, Capriles I, Maertens G, et al. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J Virol 1995; 69:773-8.
15. Gretch DR, Polyak SJ, Wilson JJ, Carithers RL Jr, Perkins JD, Corey L. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J Virol 1996; 70:7622-31.
16. Silini E, Belli L, Brambilla S, et al. Sequence variation in the hypervariable region 1 of hepatitis C virus and posttransplantation recurrent hepatitis. Liver Transpl 2003; 9:1040-7.
17. Sullivan DG, Wilson JJ, Carithers RL Jr, Perkins JD, Gretch DR. Multigene tracking of hepatitis C virus quasispecies after liver transplantation: correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns. J Virol 1998; 72:10036-43.
18. Tagariello G, Gerotto M, Pontisso P, et al. Hepatitis C virus quasispecies in the natural course of HCV-related disease in patients with haemophilia. Haemophilia 2004; 10:81-6.
19. Qin H, Shire NJ, Keenan ED, et al. HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. Blood 2005; 105:533-41.
20. Arenas JI, Gallegos-Orozco JF, Laskus T, et al. Hepatitis C virus quasispecies dynamics predict progression of fibrosis after liver transplantation. J Infect Dis 2004; 189:2037-46.
21. Kumar U, Monjardino J, Thomas HC. Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology 1994; 10:1072-5.
22. Odeberg J, Yun Z, Sonnerborg A, Bjoro K, Uhlen M, Lundeberg J. Variation of hepatitis C virus hypervariable region 1 in immunocompromised patients. J Infect Dis 1997; 175:938-43.
23. Sherman KE, Andreatta C, O'Brien J, Gutierrez A, Harris R. Hepatitis C in human immunodeficiency virus-coinfected patients: increased variability in the hypervariable envelope coding domain. Hepatology 1996; 23:688-94.
24. Toyoda H, Fukuda Y, Koyama Y, Takamatsu J, Saito H, Hayakawa T. Effect of immunosuppression on composition of quasispecies population of hepatitis C virus in patients with chronic hepatitis C coinfected with human immunodeficiency virus. J Hepatol 1997; 26:975-82.
25. Roque-Afonso AM, Robain M, Simoneau D, et al. Influence of CD4 cell counts on the genetic heterogeneity of hepatitis C virus in patients coinfected with human immunodeficiency virus. J Infect Dis 2002; 185:728-33.
26. Mao Q, Ray SC, Laeyendecker O, et al. Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies. J Virol 2001; 75:3259-67.
27. Blackard JT, Yang Y, Bordoni P, Sherman KE, Chung RT. Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy. J Infect Dis 2004; 189:1472-81.
28. Babik JM, Holodniy M. Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients. J Virol 2003; 77:1940-50.
29. Skinner HA, Sheu WJ. Reliability of alcohol use indices. The Lifetime Drinking History and the MAST. J Stud Alcohol 1982; 43:1157-70.
30. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 1999; 149:203-13.
31. Cook L, Ng KW, Bagabag A, Corey L, Jerome KR. Use of the MagNA pure LC automated nucleic acid extraction system followed by realtime reverse transcription-PCR for ultrasensitive quantitation of hepatitis C virus RNA. J Clin Microbiol 2004; 42:4130-6.
32. Davidson F, Simmonds P, Ferguson JC, et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. J Gen Virol 1995; 76:1197-1204.
33. Polyak SJ, Faulkner G, Carithers RL Jr, Corey L, Gretch DR. Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: correlation with response to interferon therapy. J Infect Dis 1997; 175:1101-7.
34. Higgins DG, Bleasby AJ, Fuchs R. CLUSTAL V: improved software for multiple sequence alignment. Comput Appl Biosci 1992; 8:189-91.
35. Korber BT. HCV sequence database: synonymous and nonsynonymous analysis program. Available at: http://hcv.lanl.gov/content/hcv-db/SNAP/SNAP.html. Accessed 15 November 2005.
36. Nei M, Gojobori T. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol 1986; 3:418-26.
37. Korber B. HIV signature and sequence variation analysis. In: Rodrigo AG, Learn GH, eds. Computational analysis of HIV molecular sequences. Dordrecht, The Netherlands: Kluwer Academic, 2000:55-72.
38. Devereux H, Telfer P, Brown D, et al. Longitudinal genotype analysis and quantification of hepatitis C virus in haemophilic patients receiving interferon-alpha therapy. J Viral Hepat 1996; 3:43-8.
39. Ni YH, Chang MH, Chen PJ, et al. Decreased diversity of hepatitis C virus quasispecies during bone marrow transplantation. J Med Virol 1999; 58:132-8.
40. Neau D, Jouvencel AC, Legrand E, et al. Hepatitis C virus genetic variability in 52 human immunodeficiency virus-coinfected patients. J Med Virol 2003; 71:41-8.
41. Gonzalez-Peralta RP, Qian K, She JY, et al. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. J Med Virol 1996; 49:242-7.
42. Sherman KE, Rouster SD, Mendenhall C, Thee D. Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease. Hepatology 1999; 30:265-70.
43. Takahashi K, Takahashi T, Takahashi S, et al. Difference in quasispecies of the hypervariable region 1 of hepatitis C virus between alcoholic and non-alcoholic patients. J Gastroenterol Hepatol 2001; 16:416-23.
44. Polyak SJ, McArdle S, Liu SL, et al. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J Virol 1998; 72:4288-96.
45. Gerotto M, Sullivan DG, Polyak SJ, et al. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. J Virol 1999; 73:7241-7.
46. Gretch DR, Bacchi CE, Corey L, et al. Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology 1995; 22:1-9.
47. Shuhart MC, Bronner MP, Gretch DR, et al. Histological and clinical outcome after liver transplantation for hepatitis C. Hepatology 1997; 26:1646-52.